

Twinox 400 mg/100 mg chewable tablets for dogs

Authorised

- Amoxicillin trihydrate
- Potassium clavulanate

Product identification

Medicine name:

Twinox 400 mg/100 mg chewable tablets for dogs

Active substance:

Amoxicillin trihydrate

Potassium clavulanate

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Amoxicillin trihydrate

459.22 milligram(s) / 1.00 Tablet

Potassium clavulanate

119.13 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01CR02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Netherlands

Package description:

Blister formed of an aluminium foil which consists of aluminum layer coated with OPA (Oriented Polyamide) film on one side and PE with desiccant on the other side and an aluminium sealing foil which consists of aluminium layer and PE coating. Blister contains 6 tablets. Carton contains 12 tablets.

Blister formed of an aluminium foil which consists of aluminum layer coated with OPA (Oriented Polyamide) film on one side and PE with desiccant on the other side and an aluminium sealing foil which consists of aluminium layer and PE coating. Blister contains 6 tablets. Carton contains 60 tablets.

Blister formed of an aluminium foil which consists of aluminum layer coated with OPA (Oriented Polyamide) film on one side and PE with desiccant on the other side and an aluminium sealing foil which consists of aluminium layer and PE coating. Blister contains 6 tablets. Carton contains 300 tablets.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:

26/07/2021

Manufacturing sites for batch release:

KRKA tovarna zdravil d.d. Novo mesto

Responsible authority:

Medicines Evaluation Board

Authorisation number:

REG NL 127075

Date of authorisation status change:

27/01/2022

Reference member state:

Ireland

Procedure number:

IE/V/0656/003

Concerned member states:

Austria Belgium France Germany Italy Netherlands Portugal

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.

Summary of Product Characteristics